Phaseline

Companies › Convergent Therapeutics

Convergent Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ac-225 rosopatamab tetraxetan
PSMA-directed radioantibody conjugated to Ac-225
FOLH1Phase 2PSMA PET-Positive Castration-Resistant Prostate CancerAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06549465Ac-225 rosopatamab tetraxetanPhase 2PSMA PET-Positive Castration-Resistant Prostate CancerOncologyAug 2027
NCT06549465Ac-225 rosopatamab tetraxetanPhase 2PSMA PET-Positive Castration-Resistant Prostate CancerOncologyAug 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

FOLH1 (1)

Companies with the same targets

Novartis Johnson & Johnson (Janssen) Telix Pharmaceuticals (Innovations) Clarity Pharmaceuticals Fusion Pharmaceuticals Five Eleven Pharma T.O.A.D. Oncology VitsGen Therapeutics Endocyte AstraZeneca

Companies built like this

CrystalGenomics Partner Therapeutics STCube Ambrx I-Mab Biopharma US

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.